These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7901457)

  • 1. Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes.
    Preudhomme C; Lepelley P; Vachee A; Soenen V; Quesnel B; Cosson A; Fenaux P
    Leukemia; 1993 Nov; 7(11):1888-90. PubMed ID: 7901457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDR1 gene expression in myelodysplastic syndrome and in acute myeloid leukemia evolving from myelodysplastic syndrome.
    Zöchbauer S; Gsur A; Götzl M; Wallner J; Lechner K; Pirker R
    Anticancer Res; 1994; 14(3B):1293-5. PubMed ID: 7915092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
    Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P
    Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis.
    Lepelley P; Soenen V; Preudhomme C; Merlat A; Cosson A; Fenaux P
    Leukemia; 1995 Apr; 9(4):726-30. PubMed ID: 7723410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.
    Lepelley P; Preudhomme C; Vanrumbeke M; Quesnel B; Cosson A; Fenaux P
    Leukemia; 1994 Aug; 8(8):1342-9. PubMed ID: 8057671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype.
    Sonneveld P; van Dongen JJ; Hagemeijer A; van Lom K; Nooter K; Schoester M; Adriaansen HJ; Tsuruo T; de Leeuw K
    Leukemia; 1993 Jul; 7(7):963-9. PubMed ID: 8100604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia.
    Preudhomme C; Lubin R; Lepelley P; Vanrumbeke M; Fenaux P
    Leukemia; 1994 Sep; 8(9):1589-91. PubMed ID: 8090036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the characteristics of folate binding proteins and its relationship with expression of multidrug resistance P-glycoprotein in myelodysplastic syndromes.
    Chen J; Li R; Yan S; Li Q; Bai T; Wang S
    Chin Med J (Engl); 1998 Mar; 111(3):235-8. PubMed ID: 10374424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
    Schneider J; Rubio MP; Barbazán MJ; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
    J Natl Cancer Inst; 1994 Jun; 86(11):850-5. PubMed ID: 7910219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists.
    Chaudhary PM; Roninson IB
    Oncol Res; 1992; 4(7):281-90. PubMed ID: 1360276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of p53 mutations using nonradioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS).
    Neubauer A; Brendel C; Vogel D; Schmidt CA; Heide I; Huhn D
    Ann Hematol; 1993 Nov; 67(5):223-6. PubMed ID: 8241345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the multidrug resistance gene in osteosarcoma: a pilot study.
    Wunder JS; Bell RS; Wold L; Andrulis IL
    J Orthop Res; 1993 May; 11(3):396-403. PubMed ID: 8100852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques.
    Brophy NA; Marie JP; Rojas VA; Warnke RA; McFall PJ; Smith SD; Sikic BI
    Leukemia; 1994 Feb; 8(2):327-35. PubMed ID: 7905944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes.
    Kurata M; Hasegawa M; Nakagawa Y; Abe S; Yamamoto K; Suzuki K; Kitagawa M
    Exp Mol Pathol; 2006 Dec; 81(3):249-54. PubMed ID: 16566920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 mutation in advanced stage of primary myelodysplastic syndrome.
    Tang JL; Tien HF; Lin MT; Chen PJ; Chen YC
    Anticancer Res; 1998; 18(5B):3757-61. PubMed ID: 9854490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of TP53 and FMS gene mutations in children with myelodysplastic syndrome.
    Jekic B; Novakovic I; Lukovic L; Kuzmanovic M; Popovic B; Milasin J; Bunjevacki G; Damnjanovic T; Cvjeticanin S; Bunjevacki V
    Cancer Genet Cytogenet; 2006 Apr; 166(2):163-5. PubMed ID: 16631474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonality studies and N-ras and p53 mutation analysis of hematopoietic cells in Fanconi anemia.
    Venkatraj VS; Gaidano G; Auerbach AD
    Leukemia; 1994 Aug; 8(8):1354-8. PubMed ID: 8057673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the p53 gene in myelodysplastic syndromes.
    Jonveaux P; Fenaux P; Quiquandon I; Pignon JM; Laï JL; Loucheux-Lefebvre MH; Goossens M; Bauters F; Berger R
    Oncogene; 1991 Dec; 6(12):2243-7. PubMed ID: 1766671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of differentiating agents on modulation of MDR1 gene expression in multidrug-resistant hematopoietic HL60/DNR cell line.
    Zhou DC; Marie JP; Maisonneuve L; Faussat-Suberville AM; Zittoun R
    Exp Hematol; 1993 Jun; 21(6):779-84. PubMed ID: 8099018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients.
    Lizard-Nacol S; Genne P; Coudert B; Riedinger JM; Arnal M; Sancy C; Brunet-Lecomte P; Fargeot P
    Anticancer Res; 1999; 19(4C):3575-81. PubMed ID: 10629655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.